We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

EVA: Evista Alendronate Comparison

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00035971
First Posted: May 8, 2002
Last Update Posted: July 19, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Eli Lilly and Company
  Purpose
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

Condition Intervention Phase
Osteoporosis Drug: raloxifene HCI and alendronate Na Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • 50-80 years of age, inclusive
  • 2 years since last menses
  • Dx femoral neck osteoporosis
  • No vertebral fractures

Exclusion Criteria

  • Poor candidate for study drugs
  • Hx of diseases affecting bone metabolism
  • Hx of breast/estrogen-dependent cancer
  • Current use of osteoporosis drug therapy
  • Hx/high risk of VTE
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035971


  Show 86 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00035971     History of Changes
Other Study ID Numbers: 5548
H3S-US-GGKO
First Submitted: May 7, 2002
First Posted: May 8, 2002
Last Update Posted: July 19, 2006
Last Verified: July 2006

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Alendronate
Raloxifene Hydrochloride
Bone Density Conservation Agents
Physiological Effects of Drugs
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators